← Back to Search

Standard Colonoscopy for Colon Adenomas

N/A

Recruiting

Led By Daniel von Renteln, Md

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Study Summary

This trial will document the colonoscopy indication, BBPS score, withdrawal time, adenoma and polyp detection rate, completeness of polypectomy, polyp location, size, surface, morphology, histopathology, and complications.

Who is the study for?

This trial is for people aged 45-80 who had a colonoscopy at CHUM between 2009 and 2022, found to have serrated lesions (SL) or high-grade dysplasia (HGD), and are due for follow-up. It's not for those with certain genetic syndromes, inflammatory bowel disease, colorectal cancer at first checkup, short life expectancy, or too early for next colonoscopy.Check my eligibility

What is being tested?

The study looks at how often high-risk adenomas come back after finding SL or HGD during a standard colonoscopy. Researchers will track details like polyp characteristics and removal success to understand the risk of future serious issues in the colon.See study design

What are the potential side effects?

Standard colonoscopies may cause discomfort, bloating, bleeding where polyps were removed, rare perforation of the colon wall, and reactions to sedatives used during the procedure.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of TMAN detection after index detection of serrated lesions

Rate of metachronous high-risk adenoma (HRA) after index detection of high-grade dysplasia (HGD)

Secondary outcome measures

Adenoma detection rates (ADR) and advanced adenoma detection rates at follow-up

Rate of T-MAN and metachronous HRA detection for the serrated lesion (SL) and HGD groups

Rate of T-MAN detection according to number, size, location, and dysplasia status of index SSPs

+8 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: ColonoscopyExperimental Treatment1 Intervention

Standard colonoscopy: All optically diagnosed polyps will be removed and sent to the CHUM pathology laboratory for histopathological evaluation according to institutional standards.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Standard Colonoscopy

2013

Completed Phase 3

~9360

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

128,907 Total Patients Enrolled

1 Trials studying Colon Adenomas

400 Patients Enrolled for Colon Adenomas

Daniel von Renteln, MdPrincipal InvestigatorCentre hospitalier de l'Université de Montréal (CHUM)

Media Library

Standard Colonoscopy Clinical Trial Eligibility Overview. Trial Name: NCT05355363 — N/A

Colon Adenomas Research Study Groups: Colonoscopy

Colon Adenomas Clinical Trial 2023: Standard Colonoscopy Highlights & Side Effects. Trial Name: NCT05355363 — N/A

Standard Colonoscopy 2023 Treatment Timeline for Medical Study. Trial Name: NCT05355363 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment open to new participants?

"The clinical trial hosted on clinicaltrials.gov is not looking for participants presently; the study, first posted on May 1st 2022 and most recently updated April 27th 2022, appears to have concluded recruitment at this time. However, there are 671 other trials that remain open and welcoming new enrollees."

Answered by AI

What is the intended outcome of this research endeavor?

"This clinical trial intends to assess the Rate of metachronous high-risk adenoma (HRA) after index detection of high-grade dysplasia (HGD) over a 1 year period. Other criteria, such as the rate of T-MAN detection for concomitant index SSP+low-risk adenoma (LRA); index SSP+ high-risk adenoma (HRA); and index SSP alone, as well as other parameters based on number, size, location, and dysplasia status will be evaluated in order to draw comprehensive conclusions."

Answered by AI

Does the age of potential participants factor into enrollment for this clinical trial?

"This clinical trial necessitates that all participants be between 45 and 80 years of age. On the other hand, there are 31 trials for minors and 660 for senior citizens."

Answered by AI

To whom would this clinical trial be most suited?

"This experiment calls for 730 senior citizens, between the ages of 45 and 80, who underwent a colonoscopy at Montreal University Hospital Center (CHUM) between 2009 to 2022. Participants must have had 1+ SL or HGD detected in that time period without proper follow-up guidelines per 2020 USMSTF regulations."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of Serrated Polyps and High-grade Dysplasia at Index Colonoscopy on Risk of Metachronous High-risk Adenomas

Daniel Von Renteln 2023. "Effect of Serrated Polyps and High-grade Dysplasia at Index Colonoscopy on Risk of Metachronous High-risk Adenomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05355363.